Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan

Clinical Genetics

Volumn 61, Issue 6, 2002, Pages 416-422

  Eto, M ^a   Saito, M ^a   Nakata, H ^b   Iwashima, Y ^c   Watanabe, K ^d   Ikoda, A ^e   Kaku, K ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

^d Ikeda Naika Clinic   (Japan)

^e Department of Internal Medicine   (Japan)

Author keywords

Apolipoprotein E; Apolipoprotein E2 2 genotype; Coronary heart disease; Diabetes mellitus; Macrophages; Remnant lipoproteins; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN E2; CHOLESTEROL; CHOLESTEROL ESTER; GLUCOSE; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; ATHEROGENESIS; BIOSYNTHESIS; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA TYPE 3; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; JAPAN; LIPID BLOOD LEVEL; MACROPHAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; CHILD; CHOLESTEROL ESTERS; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; JAPAN; LIPIDS; MACROPHAGES; MALE; MIDDLE AGED;

EID: 0036626953     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.610604.x     Document Type: Article

References (37)

1. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotien E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th edn. New York: McGraw-Hill, 1995: 1953-1980.
2. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977: 269: 604-607.
3. Mahley RW, Apolipoprotein E. Cholesterol transport protein with expanding role in cell biology. Science 1988: 240: 622-630.
4. Eto M, Watanabe K, Ishii K. Apolipoprotein E alleles and hyperlipoproteinemia in Japan. Clin Genet 1988: 34: 246-251.
5. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988: 8: 1-21.
6. Kobori S, Nakamura N, Uzawa H, Shichiri M. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E2/2 in Japan. Atherosclerosis 1988: 69: 81-88.
7. Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet 1986: 30: 422-427.
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert comittee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997: 20: 1183-1197.
9. Nakajima K, Saito T, Tamura A et al. Cholesterol in remnant-like lipoproteins in human serum using anti apo B-100 and anti apo A-1 monoclonal immmunoaffinity mixed gels. Clin Chim Acta 1993: 225: 53-71.
10. Narayan KA, Creinin HL, Kummerow FA. Disc electrophoresis of rat plasma lipoproteins. J Lipid Res 1966: 7: 150-157.
11. Havel RJ, Eder HA, Bradon HJ. The distribution and chemical composition of ultracentrfugally separated lipoprotein in human serum. J Clin Invest 1955: 34: 1345-1343.
12. Eto M, Watanabe K, Ishii K. A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application. Clin Chim Acta 1985: 149: 21-28.
13. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990: 31: 545-548.
14. Boyüm A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Invest 1968: 21 (Suppl. 96-100): 77-99.
15. Saito M, Eto M, Makino I. Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. Atherosclerosis 1997: 129: 73-77.
16. Oram JF. Receptor-mediated transport of cholesterol between cultured cells and high density lipoproteins. Methods Enzymol 1986: 129: 645-659.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein Measurement with the Folin phenol regent. J Biol Chem 1959: 193: 265-275.
18. Nakata H, Eto M, Morikawa A et al. A case of a 9-year-old girl with homozygote, apo E2/2 in whom type III hyperlipoproteinemia occurred after an operation of the craniopharyngiomia. J Jpn Ather Soc 1989: 17: 133-139.
19. Brewer HB Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983: 98: 623-640.
20. Feussner G, Wagner A, Kohl B, Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin Invest 1993: 71: 362-366.
21. Janus ED, Grant S, Lintott VJ, Wardell MR. Apolipoprotein E phenotypes in hyperlipidemic patients and their implications for treatment. Atherosclerosis 1985: 57: 249-266.
22. Kushwaha RS, Hazzard WR, Wahl PW, Hoover JJ. Type III hyperlipoproteinemia; diagnosis in whole plasma by apolipoprotein-E immunoassay. Ann Intern Med 1977: 86: 509-516.
23. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975: 82: 158-174.
24. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody apolipoprotein B-100. J Lipid Res 1992: 33: 369-380.
25. McNamara JR, Shah PK, Nakajima K et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001: 154: 229-236.
26. Wang T, Nakajima K, Leary ET et al. Ratio of remnant-like particle-cholesterol to serum total triglyceride is an effective alternative to ultracentrifugal and electrophoreic methods in the diagosis of familial type III hyperlipoproteinemia. Clin Chem 1999: 45: 1981-1987.
27. Fujishima M, Kiyohara Y, Kato I et al. Diabetes and cadiovascular disease in a prospective population survey in Japan. The Hisayama Study. Diabetes 1996: 45 (Suppl. 3): S14-S16.
28. Illingworth DR, O'Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990: 39: 403-409.
29. Civeira F, Cenarro A, Ferrando J et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients wih type III hyperlipoproteinemia. Am Heart J 1999: 138: 156-162.
30. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine β-very low density lipoproteins. J Biol Chem 1980: 255: 1839-1848.
31. Sakurai T, Kimura S, Nakano M, Kimura H. Oxidative modification on glycated low density lipoprotein in the presence of iron. Biochem Biophys Res Commun 1991: 177: 433-439.
32. Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol 1997: 17: 1707-1715.
33. Horita K, Eto M, Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 1994: 107: 203-211.
34. Eto M, Horita K, Morikawa A et al. Increased frequency of apolipoprotein E2 allele in non-insulin-dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995: 48: 288-292.
35. Chowdhury TA, Dyer PH, Kumar S et al. Association of apolipoprotein E2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 1998: 47: 278-280.
36. Suzaki K, Kobori S, Ueno S et al. Effect of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990: 80: 181-189.
37. Uterman G. Genetic polymorphism of apolipoprotein E. Impact on plasma lipoprotein metabolism. In: Crepaldi G, Tiengo A, Baggio G, eds. Diabetes, obesity and hyperlipidemias-III. Amsterdam: Elsevier Science, 1985: 1-28.